KPV

KPV is a synthetic tripeptide (lysine-proline-valine) corresponding to the C-terminal fragment of alpha-melanocyte-stimulating hormone (alpha-MSH). It is supplied here as a research compound for licensed-practitioner and laboratory use, listed in the Healing & Recovery category, and is studied in preclinical and investigational literature primarily for its reported modulatory activity in models of inflammation and tissue response. KPV is not approved by the FDA for therapeutic use and is provided strictly for research and professional reference purposes. This entry is a wholesale catalog reference for ordering practitioners and is not patient-facing marketing material.

As a short alpha-MSH-derived sequence, KPV is of interest in research settings because it is reported to retain certain signaling characteristics attributed to the parent hormone while lacking the pigmentary activity associated with the full peptide. Any discussion of observed effects reflects experimental and preclinical contexts described in the scientific literature; individual results vary and no clinical outcome is claimed or implied.

• Investigated in preclinical literature for a proposed role in modulating inflammatory signaling pathways (individual results vary)
• Studied in research models exploring tissue-recovery and wound-environment processes
• Examined in laboratory contexts for reported activity relevant to mucosal and gastrointestinal inflammation models
• Referenced in research on alpha-MSH-derived peptide fragments and their reported cytokine-modulating characteristics
• Explored in early-stage scientific literature for biological pathways associated with healing- and recovery-related research (individual results vary)

Lyophilized KPV is typically reconstituted with bacteriostatic water for injection, or with sterile water per the receiving laboratory's standard practice. Prior to reconstitution, the sealed vial is generally stored cold and protected from light; research peptides in this class are commonly kept refrigerated at approximately 2-8 C, with frozen conditions used for longer-term storage. After reconstitution, the solution is generally kept refrigerated, protected from light and repeated temperature cycling, and used within a limited window consistent with peptide-stability handling norms. Vigorous agitation should be avoided, material should be handled under appropriate aseptic conditions, and stock should be kept out of reach of unauthorized persons. All reconstitution volumes, concentrations, clinical protocols, and any administration decisions are determined solely by the licensed ordering provider in accordance with applicable regulations; the information above is storage and handling reference only and is not medical advice.

A per-lot Certificate of Analysis, HPLC purity profile, and mass-spectrometry verification are available on request for this product. Ask your account manager for the current lot documentation.

In the published research literature, KPV is described as a C-terminal tripeptide fragment of alpha-MSH that is proposed to exert anti-inflammatory modulatory activity through pathways reported as distinct from classical melanocortin-receptor pigmentation signaling. Investigators have hypothesized that KPV may influence intracellular inflammatory signaling, including reported interactions with nuclear factor-kappaB (NF-kappaB) and related cytokine cascades, and some studies have explored peptide-transporter-mediated cellular uptake as a route of entry in experimental systems. These mechanisms are described as proposed or studied within preclinical and in vitro contexts and have not been established for human therapeutic use; individual results vary.